BEIJING & CAMBRIDGE, Mass. — EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of the US Subsidiary, and Kehua Fan, M.D., as Head of Business Development. Both will report to Dr. Dong Wei, CEO of EdiGene.

Californian immuno-oncology biotech CG Oncology has reeled in a $47 million series D—and, surely, an IPO isn’t far behind—as it looks to phase 3 trials.

Rani Therapeutics has secured $69 million in new funding to move forward with the manufacturing and clinical testing of its “robotic pill”—a small, swallowable capsule that promises to shepherd more delicate drugs past the stomach before releasing them into the bloodstream.

Gilead Sciences is all about cancer these days, right? Well, no: The speedy authorization of remdesivir in COVID-19 saw its infectious disease credentials reinstated this year, and, now, it’s doubling down with a deal to buy out MYR Pharmaceuticals.

Boehringer Ingelheim has struck a deal to buy NBE-Therapeutics for €1.2 billion ($1.5 billion) to add a ROR1-directed antibody-drug conjugate (ADC) to its pipeline. The deal comes one month after Merck agreed to pay $2.8 billion to acquire VelosBio for its anti-ROR1 ADC.

The condensates space is where it’s at: With an $81 million financing, Faze Medicines is the third company in as many months to score venture dollars in pursuit of these targets. The capital will bankroll preclinical work in a pair of neurodegenerative diseases as well as support research in other areas like cancer, virology and immunology.

Activist group Public Citizen is crying foul on an “inappropriate close collaboration” between the FDA and Biogen surrounding the pharma’s controversial Alzheimer’s disease drug aducanumab and the related FDA advisory committee documents.

Amgen is set to file for FDA approval of its KRAS G12C inhibitor sotorasib by the end of the year. The plan positions Amgen to become the first company to win approval for a drug against the historically undruggable KRAS.

Boehringer Ingelheim teamed up with German biotech Labor Dr. Merk & Kollegen in 2015 on viral-based therapies. Five years on, it’s swallowing up its partner, a move it thinks will boost development of its oncolytic, or cancer-killing viruses, and cancer vaccines.

After at stint at Flagship Pioneering that was “one of the best experiences” in his career, Paul-Peter Tak, M.D., Ph.D., has a new gig. The former GlaxoSmithKline immunology chief takes over at Candel Therapeutics as the company gears up for a busy year.